In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :14

·       Intro David Eveleth, PhD :47

·       Eveleth’s background 1:05

·       What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59

·       The origins of Trefoil Therapeutics 7:27

·       FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47

·       What is your current lead investigational candidate? 14:01

·       When do you expect another read out of clinical data? 21:47

·       An adjunctive therapy with cataract surgery 18:27

·       What is the timeline of administration to patients? 19:24

·       When do you expect a readout of clinical data? 20:49

·       Is it possible to use this also for the epithelium? 21:39

·       What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07

·       For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit www.trefoiltherapeutics.com 25:53

·       Corneal disease can be fixed and better vision is possible 26:44

·       Thanks for listening 27:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.

David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics.

Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.